Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of prophylactic Neulapeg with modified FOLFIRINOX in advanced pancreatic cancer
KCT0006536Phase 2Completed
- Sponsor
- GC Biopharma
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegfilgrastim in pancreatic cancer (PC), sponsored by GC Biopharma. Started Feb 2022; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on KCT0006536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006536.